Exploring the double impact of AI on drug discovery: Innovation and Concern

Abstract:

Background: Artificial intelligence (AI) is a transformative technology that is reshaping the future of drug discovery. By enabling machines to learn from data and make decisions, AI is driving efficiency and innovation across industries, including healthcare, finance, and automation. As deep learning and neural networks continue to evolve, AI is fundamentally changing the way we conduct research, run businesses, and live our daily lives.

Aim: The study aims to explore how artificial intelligence can enhance drug discovery, optimize molecular design, and accelerate clinical research. Through the evaluation of AI-driven models, the research aims to identify efficiency improvements in pharmaceutical development and predictive analytics.

Methodology: A systematic literature review was conducted to examine and analyze existing research on AI applications in pharmaceuticals. The review focuses on AI-driven advancements in drug discovery, personalized medicine, clinical trials, and pharmaceutical manufacturing, examining both the advantages and disadvantages.

Result: Our study indicated that AI is a very effective tool for significantly reducing time, effort, and costs in drug discovery. However, our findings emphasize that AI should be used strictly as a supplementary tool rather than being relied upon as a complete solution. Maintaining rigorous human oversight and critical evaluation is essential to uphold scientific standards and to minimize the inherent limitations of AI-based methodologies. Machine learning and deep generative models are currently being used to analyze biological data, uncover novel drug candidates, and improve clinical trial efficiency. Additionally, AI-driven platforms have enabled data-sharing collaborations among industries, academia, and healthcare systems, advancing precision medicine and personalized therapies.

Conclusion: AI has not only accelerated drug discovery processes and improved the prediction of treatment outcomes but has also fostered cross-sector collaborations. These collaborations, facilitated by AI-driven platforms, are promoting innovations in precision medicine and the advancement of personalized therapies, making everyone part of this exciting journey. 

Introduction

The rapidly evolving field of drug discovery requires practical tools to achieve successful results with minimal time and cost.AI has proven to be the most effective and successful tool in meeting this demand. ⁽¹⁾ AI is profoundly impacting nearly every stage of medicine development, from the original discovery phase to the optimization of clinical trials and beyond.  AI algorithms dissect vast natural datasets (genomics, proteomics, gene expression profiles, protein-protein interaction networks) to identify disease-causing targets, such as specific proteins or genes.  Machine learning models were also found to be able to predict how an implicit drug candidate will interact with these targets, streamlining the confirmation process. Tools like DeepMind's AlphaFold have revolutionized protein structure prediction, providing invaluable insights for the design of targeted medicines. ⁽¹⁾ 

AI is transubstantiating medicine development by enhancing the capabilities of scientists, rather than replacing them. It enhances effectiveness, accelerates discoveries, and addresses patient issues by predicting drug-target interactions and optimizing clinical trials. However, to ensure the responsible adoption of AI in pharmaceutical research, it is essential to address ethical considerations such as [specific ethical considerations] and regulatory challenges like [specific regulatory challenges]. These considerations and challenges are crucial in navigating the limitations in data quality and availability. ^(2,3)

AI technologies have demonstrated remarkable capabilities in screening vast libraries of chemical compounds, offering predictive insight into key properties such as binding affinity, energy profiles, metabolic stability, solubility, and potential toxicity. ⁽⁴⁾ 

Traditionally, drug development has been a time-consuming and intricate process, relying heavily on the expertise of researchers and extensive trial-and-error experimentation. However, the landscape is rapidly evolving with the emergence of advanced AI systems, particularly large language models and generative algorithms. These innovations are reshaping the field, leading to measurable improvements in both the speed and precision of drug discovery. ^(4,5)

AI-driven exploration of chemical space enables more nuanced and targeted modifications, thereby increasing the likelihood of identifying compounds with enhanced therapeutic profiles and fewer side effects. In recent years, the pharmaceutical industry has undergone a significant shift towards data digitalization. While this transformation has unlocked new opportunities, it also presents challenges in terms of data acquisition, validation, and application to solve complex clinical problems

AI offers a powerful solution to these challenges, with its ability to process and analyze massive data sets while automating intricate workflows. At its core, AI is a technology-based framework composed of sophisticated tools and interconnected systems designed to emulate aspects of human reasoning and decision making. Nevertheless, it shouldn’t be a complete substitute for  human presence. ^(6,7)

AI, with its ability to interpret and learn from data, is continuously extending its operations in the pharmaceutical field. According to the McKinsey Global Institute, the rapid advances in AI-guided robotization are likely to transform society's work culture fully, making the future of AI in pharmaceutical research an intriguing and promising area to explore ^(7,8) 

Aim of the study:

A methodical literature review on the operations of AI in the pharmaceutical industry, covering AI-driven advancements in medicine discovery, sustained drugs, clinical trials, and pharmaceutical manufacturing. and highlighting both advantages and disadvantages.

Research Design:

This study employs a systematic literature review to analyze existing research on AI applications in pharmaceuticals. The review focuses on AI-driven advancements in drug discovery, personalized medicine, clinical trials, and pharmaceutical manufacturing including advantages and disadvantages. 

It was a two-approach study The first step involves conducting a broad search for primary applications to obtain a general overview of AI in the pharmaceutical industry. That will help identify key reputable sources, such as academic journals, research papers, and industry reports, which can then be used for more targeted information gathering. The second step is investigating each specific area (drug discovery, personalized medicine, clinical trials, and manufacturing) to gather detailed information on advancements, advantages, and disadvantages. Third and final step, synthesize common themes, emerging trends, challenges, and future prospects.

Data Collection

Sources: Peer-reviewed journals, industry reports, and case studies.

Databases: Web of Science, and Google Scholar.

Keywords:"Artificial Intelligence in Pharmaceuticals," "AI in Drug Discovery," "Machine Learning in Pharma," "AI in Clinical Trials."

Inclusion and Exclusion Criteria

Inclusion: Studies focusing on AI applications in drug development, regulatory compliance, and patient care. Those that were published in the last 5 years

Exclusion: Articles that lack empirical data or focusing solely on theoretical AI concepts without indicating use in pharmaceutical applications.

Data Analysis

Comparative Conducted by identifying and defining common themes, methodologies, and findings across all reviewed studies.

Discussion: Evaluating AI’s impact on efficiency, accuracy, and ethical considerations in pharmaceutical research.

Result and literature review

In the "How Generative AI Accelerates Drug Discovery) Bernard Marr’s 2024 study, Bernard emphasized the transformative role of generative artificial intelligence, particularly large language models (LLMs), in pharmaceutical research... By enabling the interpretation of both natural and chemical information, this technology supports pharmaceutical companies in expediting drug development processes and enhancing the efficiency with which new medicines are brought to market. In medical discovery, generative AI has been applied to complex biological processes. Mortal DNA, conforming to a 3-billion-letter sequence, has been treated as a unique language, while proteins and chemicals have been anatomized using their own structured representations. Through AI models, previously unobservable perceptivities have been uncovered, leading to an expedited medicine development process and substantial cost reductions. Given the historically low success rate of new medicine curatives, where only 10 succeed in clinical trials, advancements in effectiveness driven by AI have been mainly considered precious. AI has contributed significantly to various stages of medical discovery. Lead generation has also been enhanced, where AI has been employed to sift through vast amounts of implicit medical composites. AI-supported webbing has been used in optimization, enabling medical campaigners to be estimated efficiently; specifically, in collaboration with Recursion Pharmaceuticals, NVIDIA's AI-driven webbing capability has enabled over 2.8 quadrillion patch-target pairs to be assessed in just one week. This process that would have traditionally needed thousands of rounds. Several companies have successfully enforced AI- driven medicine discovery. Insilco Medicine, for example, has employed AI to develop treatments for idiopathic pulmonary fibrosis, reducing costs to one-tenth and shortening the development time from six to two and a half years.AI technology has also been applied to induce new COVID- 19 treatments and initiate multitudinous programs targeting various conditions, including cancer. Generative AI has significantly impacted the future of medicine development. AI-driven approaches are expected to accelerate the development of medical treatments, reducing costs and improving success rates. By decrypting complex natural and chemical information, AI has positioned itself as a trans-constructive force in healthcare, promising better patient issues and shaping the development of next-generation medicine. ⁽⁹⁾ In another study, Deep Generative Molecular Design Reshapes Drug Discovery Written by Xiangxiang Zeng, Fei Wang, Yuan Luo, Seung- gu Kang, December, 2022, they addressed, Recent advances in artificial intelligence (AI) and deep generative models have been established as precious tools in medicinal operations, particularly in medicine discovery and development. To effectively apply AI, inventors and druggies must consider multiple factors, including the selection of protocols and the integration of deep generative models into various scientific disciplines. Classical and recently developed AI approaches have been epitomized, offering a streamlined companion for computational medicine discovery. Deep generative models have been introduced from different perspectives, with theoretical frameworks used to represent chemical and natural structures. Their operations have been described, along with specialized challenges and uncharted directions. The industrialization of medicine discovery platforms has been enabled through big AI-driven data processing, leading to improvements in areas such as aging-related conditions, Alzheimer's disease, COVID-19, and antimicrobial resistance. Despite these advancements, limitations in AI operations have been highlighted, including confined model interpretability, data availability issues, and a lack of high- quality datasets. Better enterprise architecture and structure, including exascale computing and advanced technologies, have been prioritized for medicine discovery strategies. Strong data stewardship practices have been recommended to ensure standardized data governance and unbiased representation.

To elevate the reliability and usability of biomedical data sets, researchers have prioritized automated and rigorous data refinement techniques. These efforts aim to improve key dimensions of data quality, such as competence, consistency, integrity, equity, and transparency, ensuring that downstream analyses are both robust and reproducible. 

In parallel advanced data sharing of frameworks, including federated learning and collaborative platforms, are being adopted to foster deeper integration across industry, academia, and healthcare institutions. This shift is accelerating pharmaceutical innovation by enabling secure, cross disciplinary access to diverse data sets without compromising privacy or ownership.

At the molecular level, deep generative design has emerged as a powerful tool for drug discovery. These AI-driven models facilitate the creation and optimization of complex molecular structures, offering new pathways for therapeutic development. However persistent challenges such as limited generalizability and real-world applicability highlighted the need for continued refinement of these intelligent systems.

Looking ahead, the evolution of AI in medicine is expected to move beyond theoretical promise toward tangible, clinical solutions. As models become more adaptive and accessible, they will empower pharmacists and researchers with practical tools that streamline daily workflows and enhance therapeutic outcomes. ⁽¹⁰⁾

Discussion  

The most well-known use of AI is in generating textbooks and enabling bots to converse However, the real power of it lies in decrypting millions of complex DNA languages, long chains of proteins, and the secrets of molecular biology, which have taken so much time to understand, rather than being handled as quickly and efficiently as AI does. Generative AI approaches to handling vast amounts of data enable it to accelerate drug discovery, reduce substantial costs, and surpass the high rates of clinical failure.

AI improves every stage of drug development, revolutionizing the whole process, starting from early lab testing to regulatory approval. By automating complex tasks and uncovering insights across multiple areas, AI helps scientists move faster, makes more accurate decisions, and bring life-saving treatments more efficiently. It’s reflected in the following:

-Target Identification in Preclinical Testing:

AI is reshaping how we assess the safety of new drug candidate. By analyzing chemical structures with advanced predictive models, AI can anticipate potential toxic effects early in development It also supports pharmacokinetic profiling by evaluating how compounds are absorbed, distributed, metabolized, and excreted, aiming to guide the selection of promising candidates and enhance patient safety.

It provides precise genomic data by identifying the exact genes responsible for compliance, thereby giving scientists a head start.

-Lead generation in clinical study design:

Due to its capacity to create over a million protein combination possibilities, AI can generate new drug candidates in a remarkably short time—sometimes as little as hours—whereas tasks that once took years can now be accomplished in a fraction of the time. By integrating both structured and reel world data, AI brings sharper insight to clinical trial design. It helps identify the most suitable patient groups, define end points, and refine dosing strategies, while also predicting potential trial outcomes.

This foresight allows researchers to adapt proactively, minimizing risks and avoiding costly mistakes in later stages of development.

-Optimization:

At this stage of development, potential drug candidates must undergo rigorous testing to evaluate their efficacy. Generative AI plays key role in streamlining this large-scale screening process. Beyond scientific analysis, AI enhances operational efficiency by automating administrative tasks such as patient recruitment, data management, and regulatory documentation.

Predictive analytics further support strategic decision making by prioritizing high impact studies, easing local workloads, and reducing the risk of bias or manual errors.

-Regulatory submissions:

Blending AI with conventional tools enables seamless data integration and analysis, helping accelerate and submission workflows. Automated compliance checks ensure regulatory standards are met, reducing delays and improving reliability.

Natural language processing enhances the clarity of documentation, while predictive analytics help identify potential submission risks, guiding more informed strategic decisions. ⁽⁵⁾

Recent advances in AI are transforming pharmaceutical research, with NVIDIA’s partnership with Recursion Medicine serving as a compelling example. Their collaboration enables the screening of approximately 2.8 quadrillion patch target pairs within a single week, which is an achievement that would have required 100,000 times longer using conventional methods. This leap is computational efficiency underscores the disruptive potential of AI in drug discovery.

Pharmaceutical companies are increasingly leveraging generative AI to identify novel compounds, accelerate preclinical validation, and streamline the transition to clinical trial. This approach not enhances only the precision of compound target matching but also reduces the time and cost associated with early stage development.

One of the most striking demonstrations of AI’s impact comes from Insilico Medicine. The company developed a treatment for Idiopathic Pulmonary Fibrosis (IPF), a rare and life-threatening lung disease, using AI-driven methodologies. The process was completed in less than half the traditional development time and at one tenth of the cost. Beyond IPF, Insilico’s platform has produced an AI generated COVID-19 therapeutic effective across all known variants and initiated 30 additional programs targeting various cancers and chronic conditions.

This paradigm shift is more than a technological upgrade, it represents a redefinition of how medicine is conceived and delivered. I enable researchers to decode complex biological data, facilitating the creation of faster, cheaper, and more targeted therapies for diseases previously considered untreatable. The implications are profound: a future of smarter cures that not only accelerate innovation but also democratize access to life-saving treatments. ⁽⁶⁾

A recent EY-Parthenon survey of biopharmaceutical exceptive highlights where AI is expected to deliver the most transformative impact. The top areas include:

-Screening and ranking chemical compounds.

-Identifying and validating therapeutic targets.

-Predicting interactions between drugs. 

While AI's current influence on biomarker discovery and clinical trial design is considered more limited, its rapidly evolving capabilities suggest these domains will soon benefit from deeper integration. ⁽¹⁰⁾

Challenges in AI- Driven medicine Discovery

While there is considerable excitement around using AI in medicine development, we still face some significant challenges.

-One major hurdle is the data requirements for AI models, especially those using deep learning. These systems rely on large, high-quality datasets for training and validation. However, inconsistent data quality and limited sharing practices can hinder their potential. If the data is poor, the models may not work well outside of particular contexts.

To improve AI in drug discovery, we need to focus on data integration, which combines domain expertise with machine learning to enhance the usefulness of datasets. ^(7,8)

-There is also the matter of data exposure of privacy, and personal information may increase the danger of information security breaches.

This can be solved by masking personal information and using encryption to maintain data and personal information privacy.

-Data bias could be a significant concern that can affect the final result, and how it can be handled.

Expanding regions and time periods, considering more group differentiation, testing AI models, and documenting any bias mitigation will help reduce this concern and, therefore, yield more accurate results.

-The most significant concern will be entirely relying on AI and using it as a primary replacement for researchers, which can trigger all previously mentioned issues along with increase in unemployment. ⁽¹¹⁾

Limitation

Since AI is relatively new field, researches on it remains incomplete, and thus, findings are not yet conclusive. For this reason, we need more time and further experimentation to determine its full capabilities, advantages, and limitations accurately.

Conclusion

Generative AI is transforming drug discovery by speeding up and refining every stage of the process, from identifying drug targets to optimizing preclinical screenings. Despite its great potential, significant obstacles remain, particularly the reliance on high-quality, large datasets which are often fragmented and inconsistent. Overcoming these challenges will require a collaborative approach to data harmonization and sharing. The future of this technology lies in a balanced approach that combines innovation with rigorous scientific and ethical standards, ensuring that AI not only accelerates drug development but also makes precision medicine more accessible and ultimately reshapes how we treat diseases.

References

1. Visan, A.I.; Negut, I.T.; , Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery, national library of medicine, volume, 2024 Feb 7;14(2):233. 

2. Kaul, V.; Enslin, S.; Gross, S.A. History of artificial intelligence in medicine. Gastrointest. Endosc. 2020, 92, 807–812.

3. Briganti, G.; Le Moine, O. Artificial Intelligence in Medicine: Today and Tomorrow. Front. Med. 2020, 7, 27. Available online: https://www.frontiersin.org/articles/10.3389/fmed.2020.00027.

4. Dolores R Serrano , Francis C Luciano  et al, Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine, national library of medicine,2024 Oct 14;16(10):1328.

5. Marr, B., How Generative AI Accelerating Drug Discovery. 2024, 7, 1. https://bernardmarr.com/how-generative-ai-is-accelerating-drug-discovery/ 

6. Fleming, N. (2018). How artificial intelligence is changing drug discovery. Nature 557, S55–S57.

7. Schneider, P., Walters, W.P., Plowright, A.T., Sieroka, N., Listgarten, J., Goodnow,R.A.,Jr., Fisher, J., Jansen, J.M., Duca, J.S., Rush, T.S., et al. (2020). Rethinking drug design in the artificial intelligence era. Nat. Rev. Drug Discov. 19, 353–364.

8. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov. 9, 203–214 (2010).

9. Zeng, X.; Wang, F.; Luo, Y.; Kang, S.; Tang, J.; Lightstone, F.C.; Fang, E.F.; Cornell, W.; Nussinov, R.; Cheng, F., Deep generative molecular design reshapes drug discovery. Cell reports medicine, Cell press, 2022.

10. EY-Parthenon. Worldwide Transfer Pricing Reference Guide 2025. London: Ernst & Young Global Limited, 2025.  https://www.ey.com/en_gl/technical/tax-guides/worldwide-transfer-pricing-reference-guide.

11. RTS -labs. Top 7 Data Challenges Generative AI Faces And How To Overcome Them, February 12, 2025.  https://rtslab.com/generative-ai-data-challenges